The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower ...

The Food Research & Action Center calls SNAP item bans misguided, arguing the better path is incentives and access rather ...

Numerous recalls have been issued this year due to the potential for damaged products and undeclared food allergens.

The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

An ethics complaint leads to a resignation, and the agency shifts approval standards.

The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March ...

() -​Rhythm Pharmaceuticals ‌said on Friday ‌the U. Food and ⁠Drug ‌Administration has extended the ‍review period for ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.